Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07872423 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Phase III Trial of VDJ001 In Patients With Idiopathic Multicentric Castleman Disease

StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
This study adopted a multicenter, randomized, double-blind, placebo-controlled approach with the best supportive treatment design, using recombinant humanized anti-interleukin-6 receptor monoclonal antibody injection (VDJ001) to treat idiopathic multicenter Castleman disease (iMCD).
Trial Details
NCT Number NCT07872423
Lead Sponsor Beijing VDJBio Co., LTD.
Conditions
(from sponsor)		 Anti IL-6R, Castleman's Disease, Multicentric
Related terms Multi-centric Castleman's Disease
Enrollment 45 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov